We tested whether long-term administration of antioxidant vitamins C and E improves coronary and brachial artery endothelial function in patients with coronary artery disease (CAD). BACKGROUND Endothelial function is a sensitive indicator of vascular health. Oxidant stress and oxidized low-density lipoprotein (LDL) impair endothelial function by reducing nitric oxide bioavailability in the artery wall.
Excess oxygen-derived free radicals in the vascular wall and oxidation of low-density lipoprotein cholesterol (LDL) ("oxidant stress") promote cellular processes important in atherosclerosis (1, 2) . One of the earliest pathogenetic manifestations of oxidant stress is endothelial dysfunction. It is a sensitive indicator of vascular health that predicts longterm cardiovascular outcomes (3) and it is improved rapidly (within hours or weeks) by interventions that take much longer (usually years) to reduce the risk of cardiovascular events (4) .
Short-term infusions of high concentrations of the antioxidant vitamin C can correct endothelial dysfunction in patients with a variety of cardiovascular risk factors (4, 5) . These studies provided evidence that oxidant stress impairs endothelial function and served as a "proof of principle" that antioxidants can improve endothelial function. Yet, in recent large-scale clinical trials, oral antioxidants failed to reduce cardiovascular events (6 -9) . Although the large trials have been criticized (10) , the long-term effects of oral antioxidant vitamins on key biologic features of atherosclerosis are poorly defined in humans in vivo.
We conducted a randomized trial of the long-term effect of high-dose oral vitamins C and E on coronary endothelial function (primary end point) and the secondary end points of brachial artery endothelial function and oxidant stress in patients with stable coronary artery disease (CAD).
METHODS

Study design.
We conducted a randomized, double-blind, placebo-controlled study of the effects of combined vitamins C and E in patients undergoing cardiac catheterization for evaluation of CAD. The subjects had stable exertional chest pain symptoms and at least a 30% stenosis in one coronary artery as evidence of coronary atherosclerosis. Subjects were excluded if they had congestive heart failure, a left ventricular ejection fraction Ͻ40%, left main coronary artery stenosis Ͼ20%, surgical multivessel coronary disease, acute coronary syndromes with an elevation of creatinine kinase or troponin in the previous four weeks, unstable angina as defined by the Braunwald criteria (11), or if they were taking antioxidant supplements. Of the 25 patients who completed the study, 4 (16%) had mild single-vessel disease with a stenosis 30% to 50%, 17 (68%) had single-vessel disease with a stenosis Ͼ50%, 2 (8%) had two-vessel disease, and 2 (8%) had three-vessel disease (including a Ͼ50% stenosis in a side branch of a study vessel). Coronary endothelium-dependent vasomotor function was assessed using a protocol established in our laboratory (12, 13) . The study vessel was selected solely on technical suitability. Control, acetylcholine (Miochol, OMJ Pharmaceuticals Inc., San German, Puerto Rico) at estimated final concentrations of 10-8M, 10-7M, 10-6M, and nitroglycerin at 25 g/min were administered selectively into the study coronary artery at 0.8 ml/min for 3 min.
Coronary artery diameters were measured using quantitative coronary angiography (CMS-QCA, MEDIS, Leiden, Netherlands), blind to treatment and drug infusions. Vasomotor responses were calculated as percent change from baseline and the results from three artery segments were averaged (12) . Brachial artery endothelium-dependent vasomotor function. Brachial artery endothelial function was assessed within 12 h of the coronary study under the same conditions. The brachial artery was imaged in longitudinal section with a Toshiba SSH-140A with a 7.5-MHz linear array transducer (14) . A blood pressure cuff was positioned distal to the transducer, inflated to 50 mm Hg above systolic pressure for 5 min, and then released. The artery was scanned 50 to 70 s after cuff deflation (flow-mediated dilation) and 3 min after sublingual nitroglycerin (0.4 mg) (14) . Hyperemia was measured from the Doppler velocity time integral. The ultrasound images were digitized at end-diastole and brachial artery diameters were measured blind to treatment assignment using a semi-automated edge detection program (CVI Analysis, Information Integrity, Stow, Massachusetts). Flow-mediated dilation and nitroglycerin dilation were reported as percent change from baseline diameter. Measurement of blood vitamin levels and oxidant stress. Blood specimens were taken at baseline and six months and plasma was stored at Ϫ70°C. Plasma alpha-tocopherol and ascorbic acid concentrations were measured using highperformance liquid chromatography. Plasma free F2-isoprostanes were measured by stable-isotope-dilution mass spectrometry (15) in a single-batch run. The ratio of oxidized phospholipid epitopes associated with apoB-100 (detected by monoclonal antibody EO6) to number of apoB-100 particles (detected by monoclonal antibody MB24) served as an index of oxidized plasma LDL (16) . Autoantibodies to oxidized LDL (immunoglobulin G [IgG]) were determined using alkaline phosphatase-labeled goat anti-human IgG and a chemiluminescent technique using Lumi-Phos (Lumigen). Antibody binding was expressed as relative light units in 100 ms (16) . Statistical analysis. The primary and secondary end points were absolute change in endothelial function over six months. The change in coronary artery dilation to acetylcholine was skewed and reported as medians and interquartile (25% to 75%) range, and differences were tested by the rank-sum test. The change in brachial artery endothelial function was normally distributed and reported as means (and standard errors) and differences assessed by unpaired t tests. Similarly, the changes in oxidized LDL and its IgG autoantibody were normally distributed and differences assessed by unpaired t tests. All statistical tests were intention-to-treat analyses using STATA (Statacorp, College Station, Texas). Power of the study. We used the variability of change in coronary acetylcholine response observed in the vitamin group (standard deviation ϭ 13%) to estimate the power of the study to find important changes in coronary endothelial function. In other studies of coronary endothelial function, therapies that reduce coronary events generally improve the acetylcholine response by 15% to 25% (12, 17, 18) . With a standard deviation of 13%, this study had a 74% power of finding a 16% difference and a 90% power of finding a 20% difference at the 0.05 level.
RESULTS
Baseline characteristics. Thirty subjects were enrolled from September 1996 to January 1999. Of these, five discontinued shortly after enrollment. All 25 subjects returned for the six-month assessment of brachial artery endothelial function (one was not recorded because of a malfunctioning video recorder) and 18 returned for cardiac catheterization at six months. The baseline characteristics were similar for the vitamin and placebo groups ( Table 1 ).
Medications that may influence endothelial function were distributed similarly between the two groups. At enrollment, a statin was used regularly (daily for Ͼ2 weeks) by three subjects in the placebo group and five in the vitamin group. Statins were started in six subjects, yielding seven subjects in each group taking statins over the six months of the study. Three subjects in the vitamin group and two in the placebo group used angiotensin-converting enzyme inhibitors. Plasma vitamin concentrations. The baseline vitamin concentrations were similar in both groups of subjects. Over six months, the plasma alpha-tocopherol and ascorbate concentrations doubled in the subjects assigned to vitamins and were significantly greater than the change in the placebo group (Table 2) .
Coronary endothelium-dependent vasomotor function.
The baseline coronary endothelium-dependent vasomotor function was indistinguishable between the two treatment groups (Table 3 ). There was no difference in the change in endothelium-dependent responses over the six months to the maximum concentration of acetylcholine tested (Table  3 ) or in the dose response curves to increasing concentrations of acetylcholine (Fig. 1) . Endothelium-independent (nitroglycerin) responses at baseline and over six months were not different between patients assigned to antioxidant vitamins or placebo (Table 3) . Brachial artery endothelium-dependent vasomotor function. There were no differences between the treatment groups in hyperemic responses, baseline flow-mediated dilation or change in flow-mediated dilation over the six months of treatment (Table 4 , Fig. 2) . Similarly, there were no differences in the endothelium-independent nitroglycerin response at baseline or over the six months of the study (Table 4 , Fig. 2) . Measures of oxidant stress. The plasma F2-isoprostanes decreased more in patients assigned to vitamins at six months (p ϭ 0.065 overall, p ϭ 0.03 for those subjects with baseline and follow-up coronary endothelial function as- Effect of Vitamins E and C on Endothelial Function sessed) ( Table 5 ). The concentrations of plasma oxidized LDL and its IgG autoantibody did not change over the six months (Table 5) .
DISCUSSION
In this randomized, double-blind controlled study in patients with coronary atherosclerosis, six months of treatment with high-dose vitamins E and C failed to correct endothelium-dependent vasomotor dysfunction in coronary and brachial arteries. Although combined vitamins E and C doubled plasma vitamin concentrations and tended to reduce F2-isoprostanes, they did not reduce circulating oxidized LDL or autoantibodies to oxidized LDL. Our study does not support a role of combined vitamins E and C for the treatment of coronary or peripheral endothelial dysfunction in patients with CAD. Oral antioxidant vitamins and endothelial function. The role of increased oxidant stress on endothelial dysfunction in patients with a variety of coronary risk factors is supported by the reversal of this dysfunction with intra-arterial delivery of supraphysiologic doses of the antioxidant vitamin C (4).
However, studies that investigated long-term administration of oral antioxidant vitamins that achieve high physiologic concentrations have yielded contradictory effects on peripheral artery endothelial function (4, 5) . Some studies show improvement in peripheral endothelial function with oral supplementation of vitamin E (19, 20) or vitamin C (21, 22) , whereas others show a lack of benefit for vitamin E (23,24), vitamin C (25,26), or their combination (27) . Our study was the first to examine the effect of oral antioxidant vitamins on coronary endothelial function.
The inconsistent results of previous studies may be related to several factors. To effectively scavenge superoxide vitamin C must be present at concentrations of 1 to 10 mmol/l or higher (28) . These concentrations were achieved in short-term parenteral studies, but long-term oral administration typically raises vitamin C concentrations to only 0.1 mmol/l (28), similar to the present study. In the short term, vitamin C could also improve endothelial function by changes in intracellular redox state by sparing intracellular glutathione (29) , by reduced degradation of tetrahydropterin-a co-factor required for nitric oxide synthesis (30) , and by reduced protein kinase C activation (31) . The negative results of the present study suggest that the short-term effects may not persist with long-term administration of vitamin C.
Vitamin E is a lipophilic antioxidant that does not scavenge superoxide (32) . It acts by protecting LDL from oxidation (33), a property that would preserve nitric oxide (2) . However, compared to other antioxidants, vitamin E exerts a weak antioxidant effect (33) (34) (35) . Antioxidant vitamins and oxidant stress. Quantitative measurement of oxidant stress in vivo is difficult but can be based on measuring oxidatively modified molecules such as F2-isoprostanes (oxidized arachidonate containing phospholipids [15] ) and circulating oxidized LDL (16). Oxi- dized LDL is highly immunogenic as well as atherogenic, and autoantibodies to oxidized LDL are another validated measure of oxidant stress (16) . Although we found that the combination of vitamins C and E modestly reduced plasma F2-isoprostanes, it did not lower circulating oxidized LDL or autoantibodies to oxidized LDL, and this may explain the lack of benefit on endothelial function. Power of the study. Because of ethical and technical constraints of invasive investigations, studies of coronary endothelial function typically investigate fewer subjects than other end point studies. Fortunately, testing of coronary endothelial function is highly reproducible, and changes can be demonstrated in relatively small sample sizes. The sample size of nine subjects in each group in our coronary study was within the range of other studies that found improvements in coronary endothelial function with cholesterol-lowering therapies (9 to 11 subjects per group) (17, 36) . If antioxidant vitamins had an effect comparable to cholesterol-lowering therapies, our sample size had a 74% to 90% power of finding a difference at the 0.05 level. Although we can be confident that the present study excluded a substantial and hence clinically relevant benefit of antioxidants on coronary endothelial function, a modest benefit could be excluded only by a much larger study. Clinical implications. Antioxidant vitamins C and E are used widely in clinical practice. However, recent large-scale clinical trials of vitamin E (6, 8, 9) or vitamins E and C (7) have failed to reduce cardiovascular end points either in combination with other preventive therapies or alone. Our study provides a plausible explanation, as the high doses of vitamins used in this study were similar to or exceeded the doses of the large clinical trials, yet did not improve key features in the biology of atherosclerosis: endothelial function or lipid oxidation. The data in this study do not disprove the oxidant stress hypothesis. They do suggest that more potent and effective antioxidants are needed in this setting. 
